Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is seeing growth in its pharmaceutical sales, with a notable increase of 8% in the second quarter. Despite facing competitive headwinds in the glucagon generic market, the company's overall sales were bolstered by strong demand for generic epinephrine products and an additional $1.9M in sales from supplier shortages. While the discontinuation of one product at its IMS facility may have a slight impact, it is not expected to significantly affect the company's financials. Additionally, the company has a diverse geographic presence and a focus on developing challenging generic and proprietary products, providing potential for long-term growth and success.

Bears say

Amphastar Pharma is facing several headwinds including pricing challenges for their Baqsimi product, declines in sales for their injectable glucagon product, and potential competitive risks for their generic products. Additionally, there are no major catalysts expected in the near-term, leading to concerns about the company's ability to drive top-line growth. Furthermore, the recent launch of its ipratropium bromide HFA product may not provide significant revenue growth in the short term, and risks associated with potential competitors could add further pressure to the company's growth prospects. The lack of positive developments and potential risks in the coming years leads to a negative outlook for Amphastar Pharma's stock.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.